teins. Additionally, RGMa was found to be a sarcoplasmic protein with a surprisingly striated pattern. RGMa colocalization with known sarcoplasmic proteins suggested that this axon guidance molecule is a skeletal muscle sarcoplasmic protein. Western blot analysis revealed two RGMa fragments of 60 and 33 kDa, respectively, in adult skeletal muscle samples. RGMa phenotypes in skeletal muscle cells (C2C12 and primary myoblasts) were also investigated. RGMa overexpression produced hypertrophic cells, whereas RGMa knockdown resulted in the opposite phenotype. RGMa knockdown also blocked myotube formation in both skeletal muscle cell types. Our results are the first to show an axon guidance molecule as a skeletal muscle sarcoplasmic protein and to include RGMa in a system that regulates skeletal muscle cell size and differentiation. 
Introduction
Repulsive guidance molecules (RGMs) are a family of glycosylphosphatidylinositol (GPI)-anchored proteins composed of RGMa , RGMb (also known as DRAGON ), RGMc (also known as hemojuvelin , HJV and HFE2 ) and RGMd. In addition to the GPI anchor at the C-terminal region, RGM proteins also present an N-terminal signal peptide and a partial von Willebrand type D domain, which includes a catalytic cleavage site [Monnier et al., 2002; Samad et al., 2004] . Both RGMa and RGMc also present the putative RGD motif (Arg-Gly-Asp), which is possibly associated with a cell-cell adhesion mechanism.
The functional studies available thus far have revealed RGMa and RGMb phenotypes primarily in neural tissues. RGMa mutant mice showed an exencephalic phenotype [Niederkofler et al., 2004] . RGMa was also found to be a regulator of neural cell proliferation, differentiation and survival [Matsunaga et al., 2004 [Matsunaga et al., , 2006 . RGMa is also produced by microglia/macrophages at sites of central nervous system injuries [Kitayama et al., 2011] ; significant axon regeneration can be observed when RGMa is blocked [Hata et al., 2006] . Likewise, RGMa inhibition was associated with neuroprotection after cerebral ischemia [Kong et al., 2013] and with improvement in afferent synapse formation with auditory hair cells [Brugeaud et al., 2014] . The functional diversity of RGMa observed in the nervous system is based on its capacity to undergo posttranslational modifications at specific cleavage sites by the proprotein convertases SKI-1 (subtilisin kexin isozyme 1), furin and phospholipases, which result in four membrane-bound and three soluble possible RGMa forms in this system [Tassew et al., 2012] .
RGMb was found to induce adhesion of dorsal root ganglion neurons [Samad et al., 2004] . However, RGMb knockout mice die without apparent neural defects [Mueller et al., 2006] . In contrast, RGMc was found in skeletal muscle, liver, bone and cartilage [Niederkofler et al., 2004; Papanikolaou et al., 2004; Samad et al., 2004; Schmidtmer and Engelkamp, 2004; Rodriguez et al., 2007; Kanomata et al., 2009] . The lack of a functional RGMc causes a disorder known as hereditary hemochromatosis that accumulates iron in the heart, liver, skeletal muscle, endocrine glands, joints and skin cells [Pietrangelo, 2007] . No function has been assigned to RGMd thus far.
New evidence has suggested possible roles for RGMs during skeletal muscle development. RGMa , RGMb and RGMc transcripts were detected during induced differentiation of C2C12 myoblast cells [Kanomata et al., 2009] . The functional information available for RGMs thus far in this tissue was performed with a focus on RGMc because RGMc is known as the skeletal muscle form of RGMs. RGMc overexpression in C2C12 cells promoted myoblast differentiation and recruitment into myotubes Bae et al., 2009] . Additionally, RGMa and RGMb were both detected outside the nervous system, particularly at the somites of chicken embryos [Jorge et al., 2012] . RGMa transcripts were found in domains known to be the origin site of skeletal muscle pioneer and stem cells and, later, RGMa was found at the myotome. RGMb was found to overlap at sites of differentiated muscle cells and, at later stages, at craniofacial, limb and body muscles [Jorge et al., 2012] . Possible phenotypes of RGMa and RGMb in skeletal muscle cells have not been investigated thus far.
In the present study, we show new evidence of RGMa RGMb and RGMc as skeletal muscle proteins and suggest an association of RGMa with the system that regulates skeletal muscle cell size and differentiation.
Materials and Methods

Animals
Male Swiss mice (60 days old; weight: ∼ 30 g) were obtained from the vivarium of the Centro de Bioterismo, UFMG. All animal procedures were conducted following the instructions of the Ethics Commission on Animal Use (Comissão de Ética no Uso de Animais) of the UFMG (ethical approval 18/2011) and the Brazilian laws for the use of animals in scientific experiments.
Cell Culture C2C12 myoblasts were maintained in growth medium [Dulbecco's modified Eagle's medium (DMEM) with high glucose and L -glutamine (Gibco)], supplemented with 10% fetal bovine serum For primary cell cultures, muscles were harvested from the hindlimbs of 5 neonatal mice (3 days old) in Dulbecco's phosphate-buffered saline (Gibco) supplemented with a 1% penicillin/ streptomycin/amphotericin B solution and 1% gentamicin (Sigma-Aldrich). The cells were dissociated by collagenase I digestion (Gibco) and mechanically during 45 min at 37 ° C, followed by 0.25% trypsin digestion for 30 min at 37 ° C. Primary cultures were enriched for myoblasts after rounds of trypsinization and selective adhesion. The cells were seeded on 24-well plates at a cell density of 2 × 10 4 cells in growth medium supplemented with 20% FBS onto Matrigel (BD Biosciences) and kept under standard conditions. Enrichment for myoblasts was confirmed by immunofluorescence staining using anti-desmin and anti-myosin heavy-chain antibodies. Differentiation induction was performed as described for the C2C12 cell line.
Abbreviations used in this paper
Real-Time Quantitative Polymerase Chain Reaction
C2C12 cells were seeded at a cell density of 2 × 10 4 in growth medium and in duplicate in two 24-well plates (A and B biological replicates). After 24 h of incubation, the medium was removed, and the cells from 2 wells from each plate were harvested in TRIzol ® reagent (Life Technologies), which was defined as day 0. The media from the other wells were replaced to induce cell differentiation. The cells were similarly harvested in TRIzol ® reagent every day for up to 5 days, totaling 6 samples in duplicate. Total RNA was obtained from each sample following the instructions of Life Technologies. Total RNA was converted into cDNA from the poly(A) tail, following the SuperScript ® III first-strand synthesis system instructions (Life Technologies). Primers were designed using Primer3 software (http://bioinfo. ut.ee/primer3-0.4.0/) to allow the amplification of ∼ 200 bp of each reference and target gene. The following mouse genes were used as references for the quantitative analysis: β-actin (Actb: CGT-TGACATCCGTAAAGACC; TAGAGCCACCAATCCACACA), β 2 -microglobulin (B2M: CTCCCCAAATTCAAGTGT; GTGA-GC CAGGATGTAG), glyceraldehyde 3-phosphate dehydrogenase (GAPDH: GTGAAGGTCGGTGTGAACG; ATTTGATGT-TAGTGGGGTCTCG) and ribosomal protein L7 (RPL7: GA-TAACTCCTTGGTTGCTC; CCAGCGTCTCCACCTTCTAC). RGMa (CCACATCAGGAAGGCAGAAG; GCGTAGCA CT GG-GTAGGAAG), RGMb (CTCAATGCCGAATCCAGAAA; TG-CC TAACACAGCAGAATGG) and RGMc (GCTTGACCTCGG-GAAACA; AGGAGCAGCAGGAGAGTGAG) were used as targets.
Real-time quantitative polymerase chain reaction (RT-qPCR) was performed in a Rotor-Gene Q RT-PCR system (Qiagen) using 1× Platinum ® SYBR ® Green qPCR SuperMix-UDG (Life Technologies) and 0.2-0.5 μ M of each primer for a final volume of 10 μl. The samples were run in duplicate in 0.2-μl PCR tubes. The cycling parameters were as follows: 50 ° C × 2 min, 95 ° C × 2 min, followed by 40 cycles of 95 ° C × 15 s, 60-62 ° C × 30 s and 72 ° C × 20 s. The dissociation step was performed at the end of the amplification step to allow the identification of the specific melting temperature for each primer set.
Immunolocalization
Quadriceps, soleus and extensor digitorum longus (EDL) muscles were harvested from 5 adult Swiss mice and cryopreserved in an ultrafreezer. These muscles were specifically chosen in order to have the description of RGM patterns in different representative fiber types. The muscles were embedded in Tissue-Tek OCT and cut into 6-μm-thick cryosections. After 30 min of blocking with Tris-buffered saline⁄Tween casein (TBS-TC), the sections were incubated with primary antibodies at 4 ° C overnight. Corresponding fluorescent secondary antibodies were incubated for 90 min at room temperature (RT). Antibodies were used as follows: primary antibodies were diluted at 1: 100 in PBS, goat polyclonal against the C-terminal RGMa (Santa Cruz Biotechnology), rabbit polyclonal against the N-terminal RGMa (Abcam), rabbit polyclonal RGMb antibody (Santa Cruz Biotechnology), rabbit polyclonal RGMc antibody (Santa Cruz Biotechnology), mouse monoclonal titin antibody (Developmental Studies Hybridoma Bank), mouse monoclonal desmin antibody (Cell Marque) and mouse monoclonal dystrophin antibody (Developmental Studies Hybridoma Bank). Secondary antibodies were coupled to a fluorochrome, either Alexa 555 or 488 (Molecular Probes), at a 1: 500 dilution. Negative controls were determined in the absence of the respective primary antibodies on each slide.
Immunohistochemistry
Quadriceps, soleus and EDL muscles were collected from 5 adult Swiss mice and fixed in cold methanol/DMSO (80% methanol and 20% DMSO). Six-micrometer sections were blocked with TBS-TC for 30 min and incubated with antibodies against the Cand N-termini of RGMa diluted in PBS 1: 100. An LSAB System-HRP kit was used following the manufacturer's instructions (Dako). The signals were detected using 3,3 ′ -diaminobenzidine (DAB, Dako), and the sections were counterstained with Harris' hematoxylin.
Western Blot
Mouse adult quadriceps, brain and primary myoblasts were used as samples. Primary myoblasts were harvested from the hindlimbs of 5 neonatal mice (3 days old) seeded at a density of 8 × 10 4 cells/well, grown for 2 days in growth medium and incubated a further 3 days after transfection and induction of differentiation (see procedures below). The samples were homogenized with protease inhibitors (Sigma-Aldrich) as follows: Fluoret phenylmethane sulfonyl, pepstatin A, EDTA, E-64
orthovanadate sodium. After sonication, the lysates were centrifuged at 14,000 g for 30 min, and the supernatants were diluted 1: 2 in 10% SDS, glycerol and 10% bromophenol blue in 0.5 M Tris buffer (pH 6.8) and boiled for 5 min. Aliquots (20 μl) of each protein were separated in denatured 12% SDS-polyacrylamide minigels and transferred onto Hybond-ECL nitrocellulose membranes (GE Healthcare) at 100 mA for 75 min. Blocking was performed with TBS-TC buffer for 30 min at RT. The membranes were incubated for 120 min at RT with primary antibodies against the C-and N-termini of RGMa (1: 500) and a mouse β-actin antibody (1: 5,000; Abcam) as the control. After washing, the membranes were incubated for 1 h with the following secondary antibodies, diluted in PBS 1: 1,000: biotinylated anti-goat IgG antibody (Abcam), biotinylated anti-rabbit IgG antibody (Abcam) and bio-329 tinylated anti-mouse IgG antibody (Abcam), followed by incubation with a streptavidin conjugated to horseradish peroxidase (HRP) (Thermo Fisher Scientific) for 15 min at RT. The signals were detected using DAB (Sigma-Aldrich), chloramphenicol (Sigma-Aldrich) and hydrogen peroxide (Sigma-Aldrich) for 1 min at RT. Images were obtained using an Epson Perfection 4990 photo scanner.
Plasmids
Chicken RGMa CDS (GenBank accession No. AY128507) was cloned into the bicistronic plasmid pCAB-IRES-eGFP [Alvares et al., 2003 ] at the Cla I and Eco RI sites. The empty vector was used for control experiments. Short interfering RNAs (siRNAs) to promote RGMa knockdown and control siRNAs were gifts from Dr. Alain Chédotal (Centre de Recherche Institut de la Vision, Paris, France). The U6 promoter associated with the RGMa siRNA was subcloned into the pcDNA3-eGFP (Addgene) expression vector at the Eco RI and Kpn I sites.
Cell Transfections
Myoblast cells were transfected after 24 h of seeding using 0.8 μg of plasmids and Lipofectamine 2000 reagent (Life Technologies) in Opti-MEM (Gibco) following the manufacturers' instructions. After 5 h of incubation at 37 ° C and 5% CO 2 , the medium was replaced with fresh growth medium. After 24 h, the cells were trypsinized and plated onto glass slides covered with 3% gelatin in PBS. After reaching 70% confluence, the cells were cultured in DM for 3 and 5 days for immunostaining analysis. Transfection efficiency was around 5%.
Cell Culture Immunofluorescence
After 3 and 5 days in DM, both the C2C12 and primary myoblast cells were fixed with 4% paraformaldehyde and treated with 0.1% IGEPAL (Sigma-Aldrich) and 1% BSA (Sigma-Aldrich) at 37 ° C for 30 min. Rabbit anti-GFP (Abcam) and mouse anti-myosin sarcomere (MF20; Developmental Studies Hybridoma Bank), both diluted 1: 500 in 1% BSA, were incubated overnight at 4 ° C. Goat anti-rabbit antibody coupled to Alexa 488, and donkey antimouse antibody coupled to Alexa 555 (Life Technologies), both diluted 1: 500 in PBS, were used as secondary antibodies, respectively, for 90 min at 4 ° C. The nuclei were counterstained with DAPI.
Microscopy and Analysis
Immunostaining images were captured using an Olympus QColor3 imaging system with an Olympus BX51 fluorescence microscope and Image Pro Express software (version 4.5) or using a Zeiss 510 Meta confocal microscope. Immunohistochemical results were photographed using a BX41 Olympus microscope with a Q-Color 3/Olympus capture system. Adobe Photoshop CS6 software was used for image assembly. Length and width were measured in all transfected (GFP+/MHC+) cells from at least 6 wells for each treatment, using ImageJ software. For cell measurement, immuno stained sections were scanned at an objective magnification of ×20 and a projection magnification of ×2. A stage micrometer was used for standardized analysis. Digitized slides comprised TIFF images of 2,018 × 1,536 pixels. The fusion index was calculated as the ratio of the number of nuclei inside multinucleated myotubes (>3 nuclei) over the total nucleus number 100, on day 5 of myogenic differentiation.
Statistical Analysis RT-qPCR data were analyzed following the instructions of Willems et al. [2008] , with a 95% confidence interval.
RGMa in vitro phenotypes (morphometric traits of length and width, and nucleus score) were analyzed using the F test, which was verified by SASLab of SAS software and corrected when necessary. ANOVA was employed to detect the differences between two treatments, and the means (± SE) were compared by least squares (p < 0.05) using PROC GLM (SAS, 2007) . For the observed percentages, we used the χ 2 test implemented in the PROC FREQ (SAS, 2007) , considering the expected frequencies as 50% for each treatment. Any deviation between the observed and expected frequencies was significant at p < 0.05. We plotted graphs to present all of the results.
Results
Expression Pattern of RGMs during Skeletal Muscle in vitro Differentiation
To investigate possible roles of RGMs in skeletal muscle cells, we turned to the C2C12 cell lineage to detect RGM expression levels during 5 days under serum-deprived conditions to induce cell differentiation. RGMa , RGMb and RGMc transcripts were detected during all stages of C2C12 differentiation ( fig. 1 a-c) . During all differentiation stages (D1-D5), both RGMa and RGMc had higher expression levels (p < 0.05) than those detected at the corresponding D0 stage, in which cells were cultivated exclusively in growth medium ( fig. 1 a, c) . RGMb expression levels did not differ from those observed during the proliferative phase ( fig. 1 b) . These findings suggested the presence of RGMa, RGMb and RGMc transcripts during skeletal muscle cell differentiation.
RGMa, RGMb and RGMc Immunolocalization in Adult Skeletal Muscle Cells
Despite the detection of RGM transcripts in skeletal muscle cells in culture, no information regarding the localization of these proteins in adult skeletal muscle tissues has been available thus far. To determine the localization of RGMa, RGMb and RGMc in skeletal muscle cells, samples of quadriceps (mostly fast), soleus (slow) and EDL (mixed) muscles were (transversally and longitudinally) cryosectioned and subjected to immunofluorescence staining for RGMa, RGMb and RGMc. As no difference in expression patterns was observed in the different muscle types, the pictures most representative of the studied muscles were presented.
RGMa immunolocalization (C-terminal) on transversal skeletal muscle cryosections revealed signals of this axon guidance molecule detected as small dots both in the sarcolemma ( fig. 2 a, arrowheads) and all over the sarcoplasm ( fig. 2 a, arrows) . RGMb and RGMc signals in transversal cryosections revealed the presence of these proteins exclusively in the surrounding sarcolemma ( fig. 2 c, e). When longitudinal cryosections were used, RGMa immunostaining in the sarcoplasm was surprisingly found in a striated pattern ( fig. 2 b) resembling sarcomeric protein staining, whereas RGMb and RGMc were restricted to the sarcolemma ( fig. 2 d, f) .
As GPI-anchored proteins, RGMs were expected to be found exclusively in membranes. Membrane-bound and soluble forms, but no cytoplasmic forms, were previously described for RGMa in other cell types [Tassew et al., 2012] . To confirm our data, a second antibody was used against the RGMa N-terminal domain. Transversal ( fig. 3 b, e) and longitudinal ( fig. 3 a, d ) sections presented similar results for both antibodies. The striated pattern of RGMa in the sarcoplasm was also confirmed by immunohistochemistry performed using both C-and N-terminal RGMa antibodies ( fig. 4 a, c) .
Our data revealed all mammalian RGMs in the sarcolemma of skeletal muscle cells and suggested an additional role for RGMa as a sarcoplasmic striated protein.
RGMa Fragments Present in Skeletal Muscle Cells
Western blot was performed to confirm C-and N-terminal RGMa antibody specificities in skeletal muscle cells. A brain sample was used as a control. In addition to confirming antibody specificities, our results revealed the presence of two RGMa fragments, a 60-kDa fragment and a 33-kDa fragment, in skeletal muscle tissues using a Cterminal antibody ( fig. 5 a) . The N-terminal antibody allowed the identification of the 60-kDa fragment only ( fig. 5 b) . These results suggested the presence of two different RGMa fragments in skeletal muscle cells.
Colocalization of RGMa with Known Skeletal Muscle Proteins
The unexpected striated aspect of RGMa in myofibers led us to investigate whether this axon guidance protein colocalizes with known skeletal muscle proteins. For this experiment, double labeling was performed in longitudinal sections using RGMa, desmin and titin antibodies. Our results showed that RGMa colocalizes with desmin ( fig. 6 a-d) and titin ( fig. 6 e-h) proteins, suggesting an association between RGMa and the skeletal muscle sarcomeres, possibly with the Z-disks.
RGMa in vitro Phenotype
After 5 days in DM, primary muscle MHC-positive/ RGMa-positive cells presented an increase in cell width (p < 0.05) compared to the control (MHC-positive/ pCAb-positive) cells ( fig. 7 a) . The same effect was observed in RGMa-positive C2C12 cells ( fig. 7 a) . No significant difference was observed in cell length for both muscle cultures (data not shown). RGMa knockdown resulted in the opposite effect: a decrease in width of MHCpositive/RGMa-knockdown cells was observed compared to the controls ( fig. 7 c) . RGMa knockdown in C2C12 cells resulted in the same phenotype ( fig. 7 d) . Western blot analysis confirmed the efficiency of our transfections ( fig. 7 e) . Additionally, it was also possible to note that MHCpositive/RGMa-positive cells displayed a trend to increase the total number of nuclei (44.4%) compared to the control (35.6%). Taken together, these results suggested that RGMa could induce hypertrophy in skeletal muscle cells, possibly through a mechanism dependent on nuclear accretion.
RGMa and Myotube Formation
To evaluate the role of RGMa during skeletal muscle development, we scored the number of nuclei (1n, 2n-4n, and >5n) in MHC-positive/RGMa-positive and MHCpositive/RGMa-knockdown cells (primary muscle culture), and in RGMa-positive and RGMa-knockdown C2C12 cells after 3 and 5 days in DM.
MHC-positive/RGMa-positive cells did not display any significant differences in the average number of nuclei per multinucleated myotube compared to the control (data not shown). A significant difference was found when RGMa was knocked down: MHC-positive/RGMaknockdown cells were blocked from forming multinucleated myotubes after 3 and 5 days in DM ( fig. 8 a) 332 not possible to find MHC-positive/RGMa-knockdown multinucleated myotubes (presenting 2 or more nuclei; fig. 8 a) . The same results were obtained when C2C12 cells were used (data not shown).
To identify a possible effect of RGMa in myoblast fusion during cell differentiation, the fusion index was assessed in MHC-positive/RGMa-positive multinucleated myotubes after 5 days in DM. A 3-fold increase in the fusion index (p < 0.05) was observed in cells overexpressing RGMa compared to the control ( fig. 8 b) . This result suggested that RGMa-overexpressing muscle cells were more efficient to fuse.
Altogether, these results suggest that RGMa is necessary for myotube formation, as it interferes in myoblast fusion.
Discussion
RGMa is an axon guidance molecule first described as playing a role during neurogenesis as repulsive cues to axonal outgrowth [Monnier et al., 2002] . Later, other members of this family were described based on their sequence similarities: RGMb, RGMc and RGMd. Neural association was found to be restricted to RGMa and RGMb [Hata et al., 2006; Liu et al., 2009] . RGMc was described as the skeletal muscle member of this family, which was involved in the regulation of hepcidin expression [Babitt et al., 2005 [Babitt et al., , 2006 Truksa et al., 2006] and of iron homeostasis [reviewed by Papanikolaou et al., 2003] .
Recently, additional roles for RGMa and RGMb in other tissues, including skeletal muscle, have been proposed [Kanomata et al., 2009; Jorge et al., 2012] . In chicken, RGMa transcripts were found in domains of epithe- lial somites that generate skeletal muscle pioneer and stem cells, and later RGM a transcripts were found at the myotome in mature somites. RGMb transcripts were found at sites of differentiated muscle cells and, at later stages, at craniofacial, limb and body muscles [Jorge et al., 2012] . In the present study, we provided new insights into the association of RGMs and skeletal muscle cells.
RGMa, RGMb and RGMc Are All Induced during Skeletal Muscle Cell Differentiation
RGMa and RGMc were up-regulated during the induction of C2C12 cell differentiation, as detected by RTqPCR. RGMa and RGMc were both up-regulated as soon as growth medium was changed by DM (D1). Another quantitative study performed on C2C12 cells revealed RGMa and RGMb expression in both growth medium and DM, whereas RGMc was restricted to myogenin-expressing cells [Kanomata et al., 2009] . Despite the detection of RGMs on C2C12 cells, no further in vitro investigation has been performed thus far to understand the specific functions of RGMs on these cells. Our findings suggested overlapping functions of RGMa and RGMc during skeletal muscle cell differentiation.
RGMa, RGMb and RGMc Are All Found as Skeletal Muscle Proteins
Our analysis performed in adult skeletal muscle cells revealed that RGMa, RGMb and RGMc are all found in the surrounding sarcolemma. Additionally, RGMa was found in the sarcoplasm with a surprisingly striated pat- tern that was confirmed by immunofluorescence and immunohistochemistry assays. The striated pattern of RGMa resembled those of known sarcoplasmic/sarcomeric proteins, such as titin and desmin. Our findings strongly suggested that (1) RGMs play a role as skeletal muscle proteins; (2) RGMs might present overlapping or regulatory roles on the sarcolemma, and (3) RGMa plays an additional role inside the sarcoplasm of these cells most likely as a sarcomere-associated protein.
Western blot performed using RGMa C-and N-terminal antibodies on samples of skeletal muscle tissue confirmed the antibody specificities. In addition, this assay also corroborated our immunolocalization data, confirming the presence of two RGMa fragments of 60 and 33 kDa in this tissue. Multiple membrane-bound and soluble RGMa forms were described in fibroblast-like cells transfected with the full-length RGMa: four membranebound (a cleaved and an uncleaved full-length fragment, both of 60 kDa each; a C-terminal fragment of 33 kDa, and a 37-kDa fragment) and three soluble forms (two small N-terminal fragments of 30 kDa and a secreted 60 kDa form with no GPI anchor) [Tassew et al., 2009 [Tassew et al., , 2012 . The current work revealed the presence of two of these RGMa forms in skeletal muscle cells, possibly the fulllength 60 kDa and a fragment of 33 kDa, the product of an autocatalytic site present at the C-terminal domain of this protein. This result intriguingly suggested two different functions for this axon guidance molecule in skeletal muscle cells. To our knowledge, this work is the first to show RGMa inside the cytoplasm. The functions of RGMs on the sarcoplasm and sarcolemma of skeletal muscle cells remain unknown.
RGMa in vitro Phenotype
Our RGMa in vitro phenotypes, which were investigated using C2C12 and primary myoblast cells, revealed that RGMa-overexpressing cells formed larger myotubes in comparison to the control. A trend to increased total numbers of nuclei in MHC-positive/RGMa-positive cells was also observed, suggesting an association of RGMa with the mechanism of nucleus accretion during skeletal muscle differentiation. Additionally, RGMa-overexpressing muscle cells showed a higher efficiency in fusion compared to the control. RGMa knockdown revealed the opposite effect, resulting in the appearance of smaller cells, with deficient ability to form multinucleated myotubes. These results allowed us to assign a role for RGMa as a positive regulator of skeletal muscle cell size and differentiation, possibly through a mechanism of induction of cell fusion. 
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Molecules involved in different mechanisms have already been associated with myofiber cell size and differentiation; for example IGF-1 signaling molecules [Coleman et al., 1995] , the TGF-β superfamily members myostatin and bone morphogenetic protein (BMP) [McPherron and Lee, 1997; Walsh et al., 2010; Lee and McPherron, 2001] , and Pax3 and Pax7, which are known myogenic markers that induce cell size and morphology phenotypes [Collins et al., 2009] . Likewise, neogenin, netrin and RGMc have also been associated with the system that regulates skeletal muscle cell size and differentiation. Neogenin overexpression in C2C12 cells resulted in the appearance of larger myotubes and more nuclei than did C2C12/puro cells . In fact, C2C12/neo- genin cultures displayed an increase in the total number of nuclei present in MHC+ cells and in the average number of nuclei/myotubes . The same phenotype was observed when cultures were treated with netrin-2 (the chick family member most closely related to mammalian netrin-3) and when RGMc was overexpressed. However, the effects of RGMc on the cells were less pronounced than when netrins were used Bae et al., 2009] and some studies even report that RGMc overexpression in C2C12 cells has no effect on myotube formation [Huang et al., 2005; Kuninger et al., 2006] . Myoblasts derived from a homozygous gene trap mutation in the Neo1 locus developed smaller myotubes with fewer nuclei than myoblasts from control animals, with inefficient expression of muscle-specific proteins [Bae et al., 2009] . A similar phenotype was observed in GFP-sorted cells that received a neogenin RNAi vector because these cells produced smaller and fewer myotubes than did sorted control transfectants . However, the molecular mechanisms that allow RGMa (and possibly the other RGMs) to regulate skeletal muscle cell size and differentiation remain unknown and must be further addressed. The first suggestion would be through the neogenin receptor based on similar findings. Neogenin binding to the axon guidance molecule netrin was found to induce E-proteins, myogenic basic helix-loophelix factors, serum response factor and NFATc3 to drive the transcription of muscle-specific genes to regulate the actin cytoskeleton and the differentiation into multinucleated myotubes Krauss et al., 2005] . Netrin-3/neogenin binds to the CDO coreceptor to activate NFATc3, which is a candidate for the regulation of myoblast morphology, and the focal adhesion and extracellular signal-regulated kinases, which are both involved in the signaling that regulates myotube formation [Yokoyama et al., 2007; Bae et al., 2009; Quach et al., 2009] .
RGMa was also reported as a BMP coreceptor [Babitt et al., 2005; Samad et al., 2005; Babitt et al., 2006] , and BMP signaling through Smad1/5/8 was recently associated with skeletal muscle cell size regulation [Sartori et al., 2013] . The overexpression of ALK3 (BMP receptor) enhanced Smad1/5/8 phosphorylation, resulting in increased fiber size, leading to massive muscle hypertrophy. When noggin (a BMP antagonist) was overexpressed, a reduction in Smad1/5/8 phosphorylation was observed, which caused muscle atrophy [Sartori et al., 2013] . Curiously, the overexpression of both RGMa and RGMc in C2C12 cells significantly enhanced BMP activity compared with that observed for RGMa or RGMc individually [Halbrooks et al., 2007] . Conversely, the selective knockdown of RGMa, RGMb or RGMc resulted in a dramatic decrease in BMP activity, which was more pronounced when RGMa and RGMc were suppressed [Halbrooks et al., 2007] . However, RGMa was seen to have a less prominent function as a BMP coreceptor when compared to other RGMs [Wu et al., 2012] . Our results of muscle hypertrophy are also similar to ALK3 phenotypes, and one hypothesis is that RGMa may function as a BMP signaling enhancer. The involvement of RGMa and BMP signaling in muscle size requires further attention.
Taken together, these data provide insights regarding RGMa as a key player in regulating skeletal muscle size and differentiation, highlighting its possible association with the dynamic and intricate cytoskeleton of skeletal muscle cells.
